

Curriculum Vitae et Studiorum

Date Prepared: July 2026
Name: Luca Pagliaro
Born: December 18, 1989
Office Address: University of Parma, Italy
Via A. Gramsci, 14 - 43126
Work E-mail: luca.pagliaro@unipr.it
PEC: luca.pagliaro.dele@ce.omceo.it

EDUCATION

2008	Bachelor of Science Diploma di Maturità Scientifica	B.S. 100/100	Liceo Scientifico "G. Galilei", Mondragone
2014	Medicine and Surgery Laurea in Medicina e Chirurgia Board Certification in Hematology	M.D. 110/110 cum laude	Catholic University of the Sacred Heart, Rome
2019	Specializzazione Medica in Ematologia	110/110 cum laude	University of Modena and Reggio Emilia; Hematology and BMT Unit, University Hospital of Parma
2022	Ph.D. in Translational Medical and Surgical Sciences Dottorato di Ricerca	Ph.D.	University of Parma
2023	Doctor Europoeus – Translational Medical and Surgical Sciences	Ph.D.	University of Parma University of Ghent

CLINICAL AND SCIENTIFIC TRAINING

2012-14	M.D. Student	Institute of Hematology	Catholic University of the Sacred Heart, Rome
2014-15	Clinical Fellowship	Hematology and BMT Unit Mentor: Livio Pagano, M.D., L. Fianchi, M.D., Ph.D.	A. Gemelli University Policlinic, Rome
2019	Research Fellowship	Translational Hematology and Chemogenomics (THEC) Lab Mentor: G. Roti, M.D., Ph.D.	University of Parma
2022-23	Visiting Fellowship	Center for Medical Genetics, Lab of Normal and Malignant Hematopoiesis Mentor: P. Van Vlierberghe, Ph.D.	University of Ghent, Belgium
2022-24	Master Student	Master Universitario di II livello "Diagnosis and Therapy of Patients with Lymphoma and Lymphoproliferative Diseases"	University of Trieste, Sponsored by Fondazione Italiana Linfomi (FIL)

Research Fellowships

2023	Post-Doctoral Research Fellow (ADR)	Translational Hematology and Chemogenomics (THEC)	University of Parma
------	--	--	---------------------

ACADEMIC POSITION

YEAR	POSITION	DEPARTMENT	INSTITUTION
2020-23	Temporary Research Associate	Medicine and Surgery, Hematology	University of Parma
10/2023- Today	Post-Doctoral Research Scientist Ricercatore T.D.A (RTDA) MEDS-09/B "Malattie del Sangue"	Medicine and Surgery, Hematology	University of Parma

HIGHLY SPECIFIC TRAINING

2019	Special Application Training – Flow Cytometry, Miltenyi Biotec Bologna, Italy
2021	Ph.D. Academic English Course – Centro Linguistico Ateneo, Università di Parma
2022	Laboratory Animal Science Course – Faculty of Veterinary Medicine, University of Gent
2022	I Talenti dell'Open Innovation 2 – ART-ER, Regione Emilia-Romagna
2023	Grantsmanship: How to write a successful grant – AUSL and AOU Parma
2023	ICH Good Clinical Practice (GCP) E6 (R2) certification
2024	Progetto Formazione Didattica Innovativa 2024 – Università di Parma
2024	Modulo Piccoli Animali III Ed. 2024 - Corso di Formazione ed Aggiornamento per la Protezione degli Animali da Laboratorio nella Ricerca Scientifica
2025-26	MASTERY – MASTERclass in Onco-Hematology; Accademia Nazionale di Medicina
2025	EHA Topics-in-Focus Preceptorship on Precision Hematology
2026	FIL - EHA LyG Cantera: "The dynamic revolution of the therapeutic landscape in the Management of B-cell and T-cell non-Hodgkin lymphomas" – coach: prof. Zinzani

MEMBERSHIP

2018-	Italian Society of Hematology (SIE)
2019-	Italian Society of Experimental Hematology (SIES)
2021-	European Hematology Association (EHA)
2022-	Cancer Research Institute Ghent (CRIG)
2024-	Society for Functional Precision Medicine (SfPM) – Associate Member
2024-	Italian Lymphoma Foundation (FIL)

HONORS AND PRIZES

2019	Trialect traineeship program in Personalized Healthcare
2022	EHA2022 Hybrid Congress Travel Grant
2023	Under40 in Hematology – Clinical Study Project "Towards Precision Medicine in T-cell Acute Lymphoblastic Leukemia: a Functional Precision Medicine Approach"
2024	EHA-SfPM 2024 Precision Medicine Meeting, Copenhagen - Travel Grant
2025	EHA Topics-in-Focus Preceptorship on Precision Hematology – Travel Grant

FUNDING INFORMATION

2024	Bando di Ateneo per la Ricerca 2024 - Azione B – 25.000 €
2026	Associazione Chiara Tassoni 2026 – 15.000 €

REFeree ACTIVITY

2021	Journal of Cancer Research and Clinical Oncology
2023	European Journal of Pharmacology
2023	Nature npj Precision Oncology
2024	Therapeutic Advances in Drug Safety
2024	International Journal of Molecular Sciences
2025	Cells

EDUCATIONAL OUTREACH PRESENTATIONS

2025	UniStem Day, L' infinito viaggio della ricerca scientifica - Parma
2026	Unijunior Parma, VII edizione a.a.2026/27

MEETINGS

Oral presentations

2018	Attualità in Ematologia, July 6. Ferrara, Italy
2019	Emopatie rare, diagnosi di precisione e nuovi trattamenti. October 25. Perugia, Italy
2022	XVII Congresso Nazionale SIES, March 30-April 1-2. Rome, Italy

2023	ART-ER Research to Business (R2B) workshop, June 8-9. Bologna, Italy <i>"Functional Precision Medicine and Big Data: when medicine gets personal"</i>
2023	8° Workshop SIES in Ematologia Traslazionale, June 22-23. Firenze, Italy <i>"Drug Response Profiling: test ex-vivo di nuove molecole per attuare trattamenti personalizzati nelle leucemie acute linfoblastiche ad alto rischio"</i>
2024	EHA-SfPM 2024 Precision Medicine Meeting, Copenhagen, Denmark, September 26-27
2025	EHA 2025 Hybrid Congress, Milan, Italy, June 12-15
2025	Expert Meeting – DLBCL R/R NTE: Focus su: l'Immunoterapia di Combinazione con Anticorpi Ingegnerizzati anti-CD19. October 8, Parma, Italy
2026	MCL FORUM sulla valutazione terapeutica del paziente non candidabile a chemioterapia ad alte dosi. Bologna, Italy, April 29
2026	LYMPATH: Navigare l'innovazione terapeutica tra DLBCL e LF. Milan, Italy, May 27

Poster and Abstracts

2018	XV Congress of the Italian Society of Experimental Hematology, Rimini, Italy, October 18-20
2018	60 th ASH Annual Meeting, San Diego, California, December 1-4
2019	24 th EHA annual meeting, Amsterdam, Netherlands, June 12-16
2019	The 9 th International conference Notch Targeting in Cancer, Cyprus, June 26-28
2019	AACR-NCI-EORTC Molecular Targets Conference, Boston, Massachusetts, October 26-30
2019	61 st ASH Annual Meeting, Orlando, Florida, December 7-10
2021	48° Congresso Nazionale SIE e 16° Congresso Nazionale SIES, Milan, Italy, October 24-27
2022	EHA 2022 Hybrid Congress, Vienna, Austria, June 9-12
2022	64th ASH Annual Meeting and Exposition; New Orleans, Louisiana, December 10-13
2023	EHA 2023 Hybrid Congress, Frankfurt, Germany, June 8-11
2024	EHA 2024 Hybrid Congress, Madrid, Spain, June 13-16
2024	EHA-SfPM 2024 Precision Medicine Meeting, Copenhagen, Denmark, September 26-27
2024	4 th ESH How to Diagnose and Treat Lymphoma, Stockholm, Sweden, November 1-3
2025	51 st Annual Meeting of the EBMT, Florence, Italy, March 30 – April 2
2025	EHA 2025 Hybrid Congress, Milan, Italy, June 12-15
2025	52° Congresso Nazionale SIE - Milan, Italy, October 20-22
2025	67th ASH Annual Meeting and Exposition, Orlando, FL, December 6-9
2026	XIX Congresso Nazionale SIES, Florence, March 4-6.
2026	EHA 2026 Congress, Stockholm, Sweden, June 11-14

CLINICAL CONTRIBUTION

2012-15	Internship in Hematology (Policlinico Agostino Gemelli, Roma). Inpatient and outpatients care of hemato-oncological patients, including acute leukemia, myelodysplastic syndromes, myeloproliferative disorders, lymphoma and lymphoproliferative disease.
2015-19	Fellow in Hematology and Bone Marrow Transplantation (BMT) Unit (University Hospital, Parma, Italy). Hemato-oncologic inpatient management, including acute management of complications, high dose chemotherapy, PBSC mobilization, autologous stem cell transplant, allogeneic stem cell transplant from matched, unmatched sibling and haploidentical donors. Management of hematological malignancy outpatients, including acute leukemias, myeloproliferative disorders, myelodysplastic syndromes, plasma cell disorders, Hodgkin and non-Hodgkin lymphoma, chronic lymphocytic leukemia in the Day Hospital settings. Out-patient management of new patients and their diagnostic workup for general Hematology and Hemato-oncology.
2019-22	Locum Doctor Service for AUSL Parma, Servizio di Continuità Assistenziale.
2019-22	Attending physician at Hematology and BMT unit, University Hospital Parma, Italy
2022-23	Visiting physician at UZ Ghent, Belgium, Department of Hematology
2023	Out-of-hours General Practitioner's Service for AUSL Parma, Servizio di Continuità Assistenziale.
2023-	Attending Physician at Hematology, Lymphoma Unit; University Hospital of Parma

SCIENTIFIC CONTRIBUTION

1. Over the course of my scientific and medical training in Hematology, I have always been convinced that the integration between clinical activity and basic research is strongly needed to improve the understanding of cancer biology and to revolutionize our approach to cure cancer. To understand cancer biology first from

a genetic and predisposition level, moving then to cancer cell biology and signal transduction, is a process that give an overall perspective of cancer behavior for translational studies. This belief, under the early mentoring of prof. Elena Masselli, led to a co-author publication on the patients' genetic readout and chemokine levels as a predisposition to develop a secondary myelofibrosis with a more severe disease. In 2019, I joined the lab of prof. Giovanni Roti, focusing my research activity on signal transduction and drug discovery in leukemia. Specifically, I actively contributed, as part of my Ph.D. thesis, to the identification and characterization of a novel SERCA inhibitor for the treatment *NOTCH1*-dependent hematological malignancies, dissecting the relationship between the activity of SERCA and oncogenic NOTCH1 with two first-author reviews and a first author research paper. I also contributed to different projects for dissecting signal transduction in patients with aggressive types of acute leukemia, such as AML with MECOM rearrangement. This work led to the identification of a new therapeutic target in MECOM-AML, but also, it is the base of a national clinical trial on the same disease where I figure as national co-principal investigator.

- Elena Masselli, Cecilia Carrubbi, Benedetta Cambò, Giulia Pozzi, Giuliana Gobbi, Prisco Mirandola, Elena Follini, **Luca Pagliaro**, Daniela Di Marcantonio, Francesco Bonatti, Antonio Percesepe, Stephen M. Sykes, Franco Aversa & Marco Vitale. The -2518 A/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity. *Leukemia*. 2018 Oct;32(10):2266-2270.
- Pelagatti L, Pozzi G, Cortellazzi S, Mancini C, Martella E, **Pagliaro L**, Giaimo M, Roti G, Vitale M, Carubbi C and Masselli E (2024) Morphological, clinical, and molecular profiling of post-polycythemia vera accelerated/blast phase occurring with and without antecedent secondary myelofibrosis. *Front. Hematol.*3:1356561. doi: 10.3389/frhem.2024.135656.
- Marchesini M, Gherli A, Montanaro A, Patrizi L, Sorrentino C, **Pagliaro L**, Rompietti C, Kitara S, Heit S, Olesen CE, Møller JV, Savi M, Bocchi L, Vilella R, Rizzi F, Baglione M, Rastelli G, Loiacono C, La Starza R, Mecucci C, Stegmaier K, Aversa F, Stilli D, Lund Winther AM, Sportoletti P, Bublitz M, Dalby-Brown W, Roti G. Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia. *Cell Chem Biol*. 2020 Jun 18;27(6):678-697.e13.
- **Pagliaro L.**, Moron Dalla Tor L., Vento F., Andrei P., Monica L., Kleissle S., Neuenschwander M., Gherli A., Cerretani E., D'Antuono A., Simoncini E., Montanaro A., Roti G. A Chemotranscriptomic Screening Identifies The Reversal Of Glucocorticoid Resistance in *NOTCH1*-mutated T-ALL. *HemaSphere* 6():p 236-237, June 2022.
- **Luca Pagliaro**, Elisa Cerretani, Federica Vento, Anna Montanaro, Lucas Moron Dalla Tor, Elisa Simoncini, Mariateresa Giaimo, Andrea Gherli, Raffaella Zamponi, Isotta Tartaglione, Bruno Lorusso, Matteo Scita, Filomena Russo, Gabriella Sammarelli, Giannalisa Todaro, Enrico Maria Silini, Gian Matteo Rigolin, Antonio Cuneo and Giovanni Roti. CAD204520 targets NOTCH1 PEST domain mutations in lymphoproliferative disorders. *Int. J. Mol. Sci.* 2024, 25(2), 766; <https://doi.org/10.3390/ijms25020766>.
- GIMEMA AML2623. Novel approaches to target MECOM/EVI1 in acute myeloid leukemia - GIMEMA; Coordinating Center: University of Parma, P.I. prof. Giovanni Roti. Co-principal Investigator: **Luca Pagliaro**.
- Marchesini M, Gherli A, Moron Dalla Tor L, Simoncini S, Montanaro A, Thongon N, Vento F, Liverani C, Cerretani C, D'Antuono A, **Pagliaro L**, Zamponi R, Spadazzi C, Follini E, Cambò B, Falco A, Sammarelli G, Todaro G, Bonomini S, Adami V, Piazza S, Lorusso B, Mezzasoma F, Lagrasta C A M, Martelli M P, La Starza R, Cuneo A, Aversa F, Mecucci C, Quaini F, Colla S, and Roti G. Orthogonal proteogenomic approaches identify the druggable PA2G4-MYC axis in 3q26 AML. *Nat Commun* 15, 4739 (2024). <https://doi.org/10.1038/s41467-024-48953-3>.

2. Concerning translational approaches in hematological malignancies, during the last years of my PhD and my post-doctoral training, I focused on the optimization of a drug response profiling (DRP) pipeline for translational chemogenomic studies in leukemia patients. Since 2019, I promoted, implemented, and refined the DRP platform for chemogenomic high-throughput screening in patients with acute leukemias, becoming soon the project leader of the Functional Precision Medicine program in Parma. With my contribution, the FPM program implemented the platform for high-throughput screenings and started collaborations with several hematological centers in Italy for translational DRP-driven therapies in onco-hematological patients. This effort led to different regional, multicenter, and national clinical trials to inform therapies based on the integration of chemogenomic approaches. In 2022, I joined the lab of prof. Pieter Van Vlierberghe at the University of Ghent, where I launched a novel drug profiling platform that is still being used. In collaboration with the department of UZ Ghent hematology, I contributed to drug profiling-driven therapy in hematological patients with high successful rate. I still collaborate with UGhent and UZ Ghent on the optimization of their drug profiling platform. Furthermore, as a member of the Cancer Research Institute Ghent (CRIG), I'm actively involved in a specific project on drug discovery through

transcription factor targeting in acute leukemias (TaTFAL). I also contributed through the application of our DRP pipeline to further understand signal transduction and dependencies in specific subgroup of T-ALL with MYB overexpression.

- Omics approaches For Leukemia Target Identification and Matched Therapeutic Intervention FIN-RER 2020.
- NCT04582487 GIMEMA National Trial ALL-2720. Advancing chemical and genomic strategies for relapsed/refractory T-ALL and ETP-ALL.
- Reduced Intensity Conditioning (RIC) based on *ex vivo* Drug Response Profile (DRP) for allogeneic stem cell transplantation in very high risk acute myeloid leukemia: a feasibility study – Dr. Cristina Skert, UOC Ematologia-UOS Trapianto Midollo Osseo, Ospedale dell'Angelo, Mestre-Venezia.
- Targeting transcription factor addiction in acute leukemia (TaTFAL); Strategic Basic Research (SBO) Project; University of Ghent, UZ Ghent, KU Leuven, CRIG – Belgium.
- Drug Response Profiling for Hematological Malignancies – prof. Steven Goossens, prof. Tim Pieters, Department of Diagnostic Sciences, University of Ghent, Belgium.
- Almeida A, T'Sas S, **Pagliaro L**, Fijalkowski I, Sleeckx W, Van Steenberge H, Zamponi R, Lintermans B, Van Looke W, Palhais B, Reekmans A, Bardelli V, Demoen L, Reunes L, Deforce D, Van Nieuwerburgh F, Kentsis A, Ntziachristos P, Van Roy N, De Moerloose B, Mecucci C, La Starza R, Roti G, Goossens S, Van Vlierberghe P, Pieters T. Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T-cell lymphoblastic leukemia. *Hemasphere*. 2024 Mar 10;8(3):e51. doi: 10.1002/hem3.51. PMID: 38463444;
- **Pagliaro L***, Mastrodicasa E*, Pierini V, Bardelli V, Giaimo M, Zamponi R, Montanaro A, Tragni K, Arcaleni R, Massei MS, Capolsini I, Perruccio K, Varotto E, Buldini B, Gherli A, Romoli S, Matteucci C, Crocioni M, Arcioni F, Gurdo G, Cerri C, Caniglia M, Roti G, La Starza R. Ex vivo drug response profiling guides therapy in a case of high-risk acute undifferentiated leukemia with PICALM::MLLT10. *Haematologica*. 2025 Feb 27. doi: 10.3324/haematol.2024.286815. PMID: 40013393.
- **Luca Pagliaro**, Roberto Rosati, Mariateresa Giaimo, Valentina Bardelli, Raffaella Zamponi, Katia Tragni, Anna Montanaro, Andrea Gherli, Monica Messina, Alfonso Piciocchi, Giovanni Marsili, Enrico Crea, Paola Fazi, Marco Vignetti, Cristina Papayannidis, Fabio Giglio, Benedetta Cambò, Sabina Chiaretti, Matteo Piccini, Federico Lussana, Simona Sica, Patrizia Zappasodi, Lorenzo Brunetti, Eloise Beggiato, Ernesta Audisio, Erika Borlenghi, Monica Bocchia, Renato Bassan, Mariangela Di Trani, Anna Pessina, Amelia Rinaldi, Lucia Prezioso, Roberta La Starza, Cristina Mecucci and Giovanni Roti. Advancing Chemogenomic Strategies for Functional Precision Medicine in Relapsed/Refractory T-ALL and ETP-ALL: The GIMEMA ALL2720 Trial. ID: e884586a-9231-4d6e-9f19-89cdaded9bb3. *npj Precision Oncology*; doi: 10.21203/rs.3.rs-8620646/v1, *under revision*.

3. During my research training at University of Ghent, I contributed to the characterization of a murine genetic model of mantle cell lymphoma (MCL). My mentors at the University of Ghent (prof. Tim Pieters, prof. Pieter Van Vlierberghe and prof. Steven Goossens) previously generated a genetic murine MCL-like model with the overexpression of cyclin D2 and loss of p53. My contribution to the project aimed to further dissect the signal transduction dependencies of the model and apply, through the application of a drug profiling pipeline, a drug discovery approach to identify promising combination for lymphoma treatment.

- Tim Pieters, **Luca Pagliaro**, Panagiotis Ntziachristos, Pieter Van Vlierberghe, Steven Goossens. SOX11 Drives B1a Lineage Commitment and B1a/MCL-like Lymphoma Formation in Mice. *HemaSphere*, 2023, 7.Suppl: e255698f. EHA 2023 Hybrid Congress; June 8-10, Frankfurt, Germany. doi: 10.1097/01.HS9.0000967868.25569.8f.
 - **Pagliaro, Luca**; Van Steenberge, Hannah, T'Sas, Sara; Zamponi, Raffaella; Lintermans, Béatrice; Sleeckx, Wouter; Roti, Giovanni; Van Vlierberghe, Pieter; Goossens, Steven; Pieters, Tim. Drug Profiling in a Preclinical Murine Mantle Cell Lymphoma Mouse Model Identifies Novel Vulnerabilities. *HemaSphere*, P2120; 2024, EHA 2024 Hybrid Congress; June 13-16, Madrid, Spain
 - **Pagliaro, Luca**; Van Steenberge, Hannah; T'Sas, Sara; Zamponi, Raffaella; Lintermans, Beatrice; Sleeckx, Wouter; Giaimo, Mariateresa; Roti, Giovanni; Van Vlierberghe, Pieter; Goossens, Steven; Pieters, Tim. A Functional Precision Medicine Approach in Preclinical Mantle Cell Lymphoma Models Identifies Selected Target Therapies for Drug Clinical Repurposing. 4th ESH How to Diagnose and Treat Lymphoma.
 - **Luca Pagliaro**, Hannah Van Steenberge, Herlinde De Waele, Roberto Rosati, Kevin D. Hofer, Sebastian Scheinost, Junyan Lu, Sara T'Sas, Raffaella Zamponi, Béatrice Lintermans, Mariateresa Giaimo, Katia Tragni, Maaike Van Trimpont, Wouter Sleeckx, Willem Daneels, Ciel De Vriendt, Fritz Offner, Tessa Kerre, Thorsten Zenz, Giovanni Roti, Pieter Van Vlierberghe, Steven Goossens &
-

ACADEMIC CLINICAL TRIAL DEVELOPMENT

2023	Novel Approaches to Target EVI1 in Acute Myeloid Leukemia	GIMEMA	National co-Principal Investigator
------	---	--------	------------------------------------

CLINICAL TRIALS

2024	A Non-Interventional, Retrospective/Prospective, Multicenter, Single Arm Study Evaluating the Effectiveness and Safety of Polatuzumab Vedotin Plus R-CHP in Real-World Clinical Practice Among Italian Adult Patients with Untreated Diffuse Large B-Cell Lymphoma - POLARWOLF STUDY (PXL 287550)	Roche	Local Principal Investigator Parma
2024	A prospective, observational cohort study to evaluate the clinical impact of novel monoclonal antibodies (MAB) in B-cell Non-Hodgkin Lymphoma (NHL) in Italian clinical practice – FIL MAB	FIL	Local Principal Investigator Parma
2025	Italian real-world study on epcoritamab in patients with relapsed or refractory diffuse large B-cell lymphoma - EPKEY_HSR	IRCCS OSR	Local Principal Investigator Parma
2026	A Phase 2/3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Fofotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma	Acrotech Biopharma Inc.	Local Principal Investigator Parma

TEACHING AND MENTORING ACTIVITY

2019-	Student tutoring activity	Medicine and Surgery, Hematology Module	University of Parma
2019-	Student tutoring activity	Medical, Veterinary and Pharmaceutical Biotechnology, Molecular Therapies Module	University of Parma
2021-24	Honorary Scholar Cultore della Materia, Malattie del Sangue - MED/15	Department of Medicine and Surgery	University of Parma
2024-	Hematology	Medicine and Surgery	University of Parma
2024-	Medical Clinic Course, Hematology Module	Nursing Degree Course	University of Parma

PUBLICATIONS

ORCID ID: 0000-0001-5500-3522

WoS ResearcherID: AAC-5779-2022

Scopus AuthorID: 57201319402

Google Scholar: <https://scholar.google.com/citations?user=B3esc1gAAAAJ&hl=it>

H index

Scopus: 6

Google Scholar: 7

Papers

Anna Montanaro, Gregorio Monica, Raffaella Zamponi, Anna D'Antuono, Alice Andreani, Pietro Andrei, Angela Su, Alessia Ciringione, Gabriella Sammarelli, Giannalisa Todaro, Roberto Rosati, Roberta La Starza, Cristina Mecucci, Loredana Elia, Andrea Gherli, Federica Vento, Elisa Simoncini, Bruno Lorusso, Costanza Anna Maria Lagastra, Mariateresa Giaimo, **Luca Pagliaro**, Matteo Marchesini, Connie R Jimenez, Federico Quaini, Kimberly Stegmaier, and Giovanni Roti. Inhibition of the Atypical Kinase WNK1 as a Therapeutic Strategy in TAL-related T-cell Acute Lymphoblastic Leukemia. *Blood*. 2026 May 19: blood.2025029901. doi: 10.1182/blood.2025029901.

Francesca Maria Quaglia, Lara Mannelli, **Luca Pagliaro**, Greta Scapinello, Luana Schiattone, Mirko Farina, Mattia Novo, Piera Angelillo, Roberta Sciarra, Elena Maiolo, Elisa Lucchini, Valeria Tomarchio, Chiara Ghiggi, Sabrina Pelliccia, Miriam Marangon, Luigi Marcheselli, Francesco Zaja. Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real-Life Multicenter Experience. Results From the REDOT_MCL Study. *Hematological Oncology*: e70190. <https://doi.org/10.1002/hon.70190>.

Danika Di Giacomo, Petri Pölönen, Valentina Bardelli, Shunsuke Kimura, Valentina Pierini, **Luca Pagliaro**, Silvia Arniani, Yunchao Chang, Qingsong Gao, Lindsey E. Montefiori, Yiming Wu, Chun Shik Park, William C Wright, Federica Vento, Huimei Wei, Caterina Matteucci, Shaohua Lei, Wojciech Rosikiewicz, Carlotta Nardelli, Anair Graciela Lema Fernandez, Anna Østergaard, Emily A. Backhaus, Pradyumna Baviskar, Marco Cerrano, Matteo Leoncin, Atsushi Manabe, Shinsuke Hirabayashi, Junko Takita, Daisuke Hasegawa, Satoshi Miyamoto, Antonio Macchiarulo, Jason Xu, David Trent Teachey, Giovanni Roti, Ilaria Iacobucci, Roberta La Starza, Cristina Mecucci, Charles G. Mullighan; Deregulation of FOXF1/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia. *Blood* 2026; blood.2025031402. doi: <https://doi.org/10.1182/blood.2025031402>

Farina, M., Maiolo, E., Ghiggi, C., Angelillo P., Novo M., Quaglia F.M., Schiattone L., Battista M.L., Mannelli L., Tomarchio V., Lucchini E., **Pagliaro L.**, Scapinello G., Marangon M., Pelliccia S., Sciarra R., Russo D. & Zaja F. Multicenter real-life evaluation of the Post-CAR prognostic index for patients with large B-cell lymphoma after CAR-T failure. *J Hematol Oncol* 19, 4 (2026). <https://doi.org/10.1186/s13045-025-01771-6>

Pagliaro L*, Mastrodicasa E*, Pierini V, Bardelli V, Giaimo M, Zamponi R, Montanaro A, Tragni K, Arcaleni R, Massei MS, Capolsini I, Perruccio K, Varotto E, Buldini B, Gherli A, Romoli S, Matteucci C, Crocioni M, Arcioni F, Gurdo G, Cerri C, Caniglia M, Roti G, La Starza R. Ex vivo drug response profiling guides therapy in a case of high-risk acute undifferentiated leukemia with *PICALM::MLLT10*. *Haematologica*. 2025 Feb 27. doi: 10.3324/haematol.2024.286815. PMID: 40013393.

Vanhooren, J.; Deneweth, L.; **Pagliaro, L.**; Ren, Z.; Giaimo, M.; Zamponi, R.; Roti, G.; Depreter, B.; Hofmans, M.; De Moerloose, B.; et al. Nidogen-1, a Player in KMT2A-Rearranged Pediatric Acute Myeloid Leukemia. *Int. J. Mol. Sci.* 2025, 26, 3011. <https://doi.org/10.3390/ijms26073011>

Luca Pagliaro, Sai-Juan Chen, Daniel Herranz, Cristina Mecucci, Christine J. Harrison, Charles G. Mullighan, Ming Zhang, Zhu Chen, Nicolas Boissel, Stuart S. Winter, Giovanni Roti. Acute lymphoblastic leukaemia. *Nat Rev Dis Primers* 10, 41 (2024). <https://doi.org/10.1038/s41572-024-00525-x>.

Lorenzo Guidetti, Riccardo Castelli, Alfonso Zappia, Francesca Romana Ferrari, Carmine Giorgio, Elisabetta Barocelli, **Luca Pagliaro**, Federica Vento, Giovanni Roti, Laura Scalvini, Federica Vacondio, Silvia Rivara, Marco Mor, Alessio Lodola, Massimiliano Tognolini. Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line. *Eur J Med Chem*. 2024 Oct 5:276:116681. doi: 10.1016/j.ejmech.2024.116681.

Marchesini M, Gherli A, Moron Dalla Tor L, Simoncini S, Montanaro A, Thongon N, Vento F, Liverani C, Cerretani C, D'Antuono A, **Pagliaro L**, Zamponi R, Spadazzi C, Follini E, Cambò B, Falco A, Sammarelli G, Todaro G, Bonomini S, Adami V, Piazza S, Lorusso B, Mezzasoma F, Lagrasta C A M, Martelli M P, La Starza R, Cuneo A, Aversa F, Mecucci C, Quaini F, Colla S, and Roti G. Orthogonal proteogenomic approaches identify the druggable PA2G4-MYC axis in 3q26 AML. *Nat Commun* 15, 4739 (2024). doi: 10.1038/s41467-024-48953-3.

Pelagatti L, Pozzi G, Cortellazzi S, Mancini C, Martella E, **Pagliaro L**, Giaimo M, Roti G, Vitale M, Carubbi C and Masselli E (2024) Morphological, clinical, and molecular profiling of post-polycythemia vera accelerated/blast phase occurring with and without antecedent secondary myelofibrosis. *Front. Hematol.* 3:1356561. doi: 10.3389/frhem.2024.135656.

Almeida A, T'Sas S, **Pagliaro L**, Fijalkowski I, Sleenckx W, Van Steenberge H, Zamponi R, Lintermans B, Van Looke W, Palhais B, Reekmans A, Bardelli V, Demoen L, Reunes L, Deforce D, Van Nieuwerburgh F, Kentsis A, Ntziachristos P, Van Roy N, De Moerloose B, Mecucci C, La Starza R, Roti G, Goossens S, Van Vlierberghe P, Pieters T. Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T-cell lymphoblastic leukemia. *Hemasphere*. 2024 Mar 10;8(3):e51. doi: 10.1002/hem3.51. PMID: 38463444.

Luca Pagliaro, Elisa Cerretani, Federica Vento, Anna Montanaro, Lucas Moron Dalla Tor, Elisa Simoncini, Mariateresa Giaimo, Andrea Gherli, Raffaella Zamponi, Isotta Tartaglione, Bruno Lorusso, Matteo Scita, Filomena Russo, Gabriella Sammarelli, Giannalisa Todaro, Enrico Maria Silini, Gian Matteo Rigolin, Antonio Cuneo and Giovanni Roti. CAD204520 targets NOTCH1 PEST domain mutations in lymphoproliferative disorders. *Int. J. Mol. Sci.* 2024, 25(2), 766; doi: 10.3390/ijms25020766.

Leoncin M, La Starza R, Roti G, **Pagliaro L**, Bassan R, Mecucci C. Modern treatment approaches to adult acute T-lymphoblastic and myeloid/T-lymphoblastic leukemia: from current standards to precision medicine. *Curr Opin Oncol.* 2022 Nov 1;34(6):738-747. doi: 10.1097/CCO.0000000000000900. Epub 2022 Aug 26. PMID: 36017547.

Montanaro A, Kitara S, Cerretani E, Marchesini M, Rompietti C, **Pagliaro L**, Gherli A, Su A, Minchillo ML, Caputi M, Fioretzaki R, Lorusso B, Ross L, Alexe G, Masselli E, Marozzi M, Rizzi FMA, La Starza R, Mecucci C, Xiong Y, Jin J, Falco A, Knoechel B, Aversa F, Candini O, Quaini F, Sportoletti P, Stegmaier K, Roti G. Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia. *Cell Death Dis.* 2022 Jun 17;13(6):551. doi: 10.1038/s41419-022-05002-5. PMID: 35710782; PMCID: PMC9203761.

Pagliaro L, Marchesini M, Roti G. Targeting oncogenic Notch signaling with SERCA inhibitors. *J Hematol Oncol.* 2021 Jan 6;14(1):8. doi: 10.1186/s13045-020-01015-9. PMID: 33407740; PMCID: PMC7789735.

Pagliaro L, Sorrentino C, Roti G. Targeting Notch Trafficking and Processing in Cancers. *Cells.* 2020 Sep 29;9(10):2212. doi: 10.3390/cells9102212. PMID: 33003595; PMCID: PMC7600097.

Marchesini M, Gherli A, Montanaro A, Patrizi L, Sorrentino C, **Pagliaro L**, Rompietti C, Kitara S, Heit S, Olesen CE, Møller JV, Savi M, Bocchi L, Vilella R, Rizzi F, Baglione M, Rastelli G, Loiacono C, La Starza R, Mecucci C, Stegmaier K, Aversa F, Stilli D, Lund Winther AM, Sportoletti P, Bublit M, Dalby-Brown W, Roti G. Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia. *Cell Chem Biol.* 2020 Jun 18;27(6):678-697.e13. doi: 10.1016/j.chembiol.2020.04.002. Epub 2020 May 7. PMID: 32386594; PMCID: PMC7305996.

Elena Masselli, Cecilia Carrubbi, Benedetta Cambò, Giulia Pozzi, Giuliana Gobbi, Prisco Mirandola, Elena Follini, **Luca Pagliaro**, Daniela Di Marcantonio, Francesco Bonatti, Antonio Percesepe, Stephen M. Sykes, Franco Aversa & Marco Vitale. The -2518 A/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity. *Leukemia*. 2018 Oct;32(10):2266-2270. doi: 10.1038/s41375-018-0088-y. Epub 2018 Mar 6. PMID: 29568096; PMCID: PMC6170394.

Abstract/Meetings/Other contributions

Anna Montanaro, Gregorio Monica, Anna D'antuono, Raffaella Zamponi, Alice Andreani, Gabriella Sammarelli, Giannalisa Todaro, Roberta La Starza, Cristina Mecucci, Mariateresa Giaimo, Andrea Gherli, Federica Vento, Bruno Lorusso, Elisa Simoncini, **Luca Pagliaro**, Connie Jimenez, Federico Quaini, Giovanni Roti. Targeting the Atypical Protein Kinase WNK1 in TAL1-Related T-Cell Acute Lymphoblastic Leukemia. S105. 2026;10(S1). Haemasphere. EHA2026 Congress, 11-14 June, Stockholm, Sweden.

D. Di Giacomo, P. Pölönen, V. Bardelli, S. Kimura, V. Pierini, **L. Pagliaro**, S. Arniani, Y. Chang, Q. Gao, L. E. Montefiori, C. Matteucci, S. Lei, W. Rosikiewicz, C. Nardelli, A. G. Lema Fernandez, A. Østergaard, E. A. Backhaus Wagner, P. Baviskar, M. Cerrano, M. Leocin, A. Manabe, S. Hirabayashi, J. Takita, D. Hasegawa, S. Miyamoto, A. Macchiarulo, J. Xu, D.T. Teachey, G. Roti, I. Iacobucci, R. La Starza, C. Mecucc2, C. G. Mullighan. Ectopic Activation of FOXF1 And FENDRR by t(14;16)(q32;q24) Identifies a High-Risk T-ALL/MPAL Subtype. S107. 2026;10(S1). Haemasphere. EHA2026 Congress, 11-14 June, Stockholm, Sweden.

M. Giaimo, B. Cambò, **L. Pagliaro**, R. Zamponi, R. Rosati, D. Forte, A. Gherli, M. Crugnola, L. Prezioso, A. Rinaldi, A. Pessina, S. Bonomini, G. Sammarelli, A. Montanaro, F. Pasini, I.S. Polanco, D. Ocadlikova, A. Ferrari, C. Salvesi, A. Spedaluzzi, M. Paganelli, P. Tosi, A. Tieghi, D. Vallisa, A. Cuneo, F. Lanza, G. Simonetti, G. Martinell, A. Curti, G. Roti. Integrating pharmacogenomics and microenvironment profiling in high-risk leukemias. XIX Congress of the Italian Society of Experimental Hematology, Florence, 4-6 March 2026.

A. Montanaro, G. Monica, A. D'antuono, R. Zamponi, G. Sammarelli, G. Todaro, R. La Starza, C. Mecucci, M. Giaimo, A. Gherli, F. Vento, B. Lorusso, E. Simoncini, **L. Pagliaro**, C. R. Jimenez, F. Quaini, G. Roti. Identification of WNK1 as a druggable target in TAL1-related T-cell acute lymphoblastic leukemia. XIX Congress of the Italian Society of Experimental Hematology, Florence, 4-6 March 2026.

D. Di Giacomo, P. Pölönen, V. Bardelli, S. Kimura, V. Pierini, **L. Pagliaro**, S. Arniani, Y. Chang, Q. Gao, L. E. Montefiori, C. Matteucci, S. Lei, W. Rosikiewicz, C. Nardelli, A. G. Lema Fernandez, A. Østergaard, E. A. Backhaus Wagner, P. Baviskar, M. Cerrano, M. Leocin, A. Manabe, S. Hirabayashi, J. Takita, D. Hasegawa, S. Miyamoto, A. Macchiarulo, J. Xu, D.T. Teachey, G. Roti, I. Iacobucci, R. La Starza, C. Mecucc2, C. G. Mullighan. Ectopic activation of FOXF1 and FENDRR by t(14;16)(q32;q24) identifies a high-risk T-ALL/MPAL subtype. XIX Congress of the Italian Society of Experimental Hematology, Florence, 4-6 March 2026.

F. Servoli, M. Giaimo, V. Pierini, V. Bardelli, S. Arniani, M. Lucarelli, C. Matteucci, B. Crescenzi, S. Romoli, **L. Pagliaro**, R. Zamponi, A. Fiou, M. Vecchi, F. Landuzzi, F. Forghieri, A. Curti, B. Cambò, C. Pasciolla, F. Lessi, F. Lussana, A. Cavalli, G. Roti, M.P. Martelli, R. La Starza. Biallelic loss of RB1 and LPAR6 at 13q14 drives key cell cycle abnormalities in T-cell acute lymphoblastic leukemia. XIX Congress of the Italian Society of Experimental Hematology, Florence, 4-6 March 2026.

V. Bardelli, **L. Pagliaro**, V. Pierini, S. Arniani, F. Servoli, M. Lucarelli, S. Sica, M. Cerrano, F. Giglio, M. Delia, B. Cambo', M. Annunziata, S. Trappolini, F. Forghieri, M. Lunghi, P. Zappasodi, M. Piccini, C. Matteucci, A. Tafuri, P. Grammatico, M. Martelli, C. Mecucci, G. Roti, R. La Starza. Combined nf1/suz12 haploinsufficiency drives aberrant activation of the RAS signaling cascade in immature hoxa-positive T-ALL. XIX Congress of the Italian Society of Experimental Hematology, Florence, 4-6 March 2026.

Tim Pieters, **Luca Pagliaro**, André De Almeida, Fritz Offner, Tom Taghon, Pieter Van Vlierberghe, Steven Goossens. Sox11-induced reprogramming of B2 cells to a B1a-like phenotype promotes Mantle Cell Lymphoma in mice. Oral, Blood 146 (2025) 143. <https://doi.org/10.1182/blood-2025-143>. The 67th ASH Annual Meeting, Orlando (FL), December 6-9.

Luca Pagliaro, Mariateresa Giaimo, Roberto Rosati, Raffaella Zamponi, Davide Carnevali, Benedetta Cambò, Valentina Bardelli, Katia Tragni, Anna Montanaro, Monica Messina, Alfonso Picciocchi, Giovanni Marsili, Enrico Crea, Fabio Ciceri, Sabina Chiaretti, Cristina Papayannidis, Matteo Piccini, Alessandro Rambaldi, Simona Sica, Patrizia Zappasodi, Amelia Rinaldi, Lucia Prezioso, Cristina Mecucci, Roberta La Starza, Giovanni Roti. Early Results from the GIMEMA ALL2720 Trial: Chemogenomic Strategies In Relapsed/Refractory T-ALL And ETP-ALL. *Discussed Poster Presentation*. ID: DP087. 52° Congresso Nazionale SIE - Milan, Italy, October 20-22.

M. Messina, G. Marsili, **L. Pagliaro**, M. Giaimo, V. Bardelli, S. Arniani, V. Pierini, E. Crea, S. Orlando, A. Rughini, V. Sargentini, L. Di Donato, A. Piciocchi, P. Fazi, M. Vignetti, R. La Starza, G. Roti, C. Mecucci. The GIMEMA ALL2720 Study Explores the Feasibility Of Integrating Drug Response Profiling With Genomic Analyses To Guide Treatment Decisions In R/R T-LLI and ETP-ALL. *ePoster*. ID: P054. 52° Congresso Nazionale SIE - Milan, Italy, October 20-22.

E Lucchini, R Sciarra, V Tomarchio, S Pelliccia, M Marangon, E Maiolo, M Novo, L Schiattone, M Farina, G Scapinello, FM Quaglia, J Olivieri, **L Pagliaro**, P Angelillo, L Mannelli, C Ghiggi, F Zaja. The role of stem cell transplantation in patients with relapsed/refractory classical Hodgkin lymphoma treated with checkpoint inhibitors: italian multicenter experience. ID: C034. Pag 29. Abstract Book of the 52nd Congress of the Italian Society of Hematology. October 20-22, Milan, Italy.

M. Farina, E. Maiolo, C. Ghiggi, P. Angelillo, M. Novo, F. M. Quaglia, L. Schiattone, L. Mannelli, V. Tomarchio, E. Lucchini, **L. Pagliaro**, G. Scapinello, M. Marangon, S. Pelliccia, R. Sciarra, F. Zaja. A Multi-Center Real-Life Analysis on Patients with Large B-Cell Lymphoma after Failure of CAR-T Cells Therapy. ID: DP073. Pag 109. Abstract Book of the 52nd Congress of the Italian Society of Hematology. October 20-22, Milan, Italy.

Francesca Maria Quaglia, Lara Mannelli, **Luca Pagliaro**, Greta Scapinello, Luana Schiattone, Mirko Farina, Mattia Novo, Piera Angelillo, Roberta Sciarra, Elena Maiolo, Elisa Lucchini, Valeria Tomarchio, Chiara Ghiggi, Sabrina Pelliccia, Miriam Marangon, Luigi Marcheselli, Francesco Zaja. Ibrutinib Dose Modifications in Mantle Cell Lymphoma: an Italian Real-Life Multicenter Experience. Results from the REDOT_MCL Study. ID: P001. Pag. 142. Abstract Book of the 52nd Congress of the Italian Society of Hematology. October 20-22, Milan, Italy.

Luca Pagliaro, Mariateresa Giaimo, Roberto Rosati, Raffaella Zamponi, Davide Carnevali, Benedetta Cambò, Valentina Bardelli, Katia Tragni, Anna Montanaro, Monica Messina, Alfonso Piciocchi, Giovanni Marsili, Enrico Crea, Fabio Ciceri, Sabina Chiaretti, Cristina Papayannidis, Matteo Piccini, Alessandro Rambaldi, Simona Sica, Patrizia Zappasodi, Roberta La Starza, Cristina Mecucci, Giovanni Roti. Advancing Chemogenomic Strategies for Functional Precision Medicine in Relapsed/Refractory T-ALL and ETP-ALL: Preliminary Results of the GIMEMA ALL2720 Trial. ID: S115. *Oral Presentation*. EHA 2025 Hybrid Congress, June 12-15, Milan, Italy.

Francesca Maria Quaglia, Lara Mannelli, **Luca Pagliaro**, Greta Scapinello, Luana Schiattone, Mirko Farina, Mattia Novo, Piera Angelillo, Roberta Sciarra, Elena Maiolo, Elisa Lucchini, Valeria Tomarchio, Chiara Ghiggi, Sabrina Pelliccia, Miriam Marangon, Luigi Marcheselli, Francesco Zaja. Ibrutinib Dose Modifications in Mantle Cell Lymphoma: an Italian Real-Life Multicenter Experience. Results from the REDOT_MCL Study. Abstract Book: n.615. 18th International Conference on Malignant Lymphoma (ICML), June 17-21, Lugano, Switzerland.

Francesca Maria Quaglia, Lara Mannelli, **Luca Pagliaro**, Greta Scapinello, Luana Schiattone, Mirko Farina, Mattia Novo, Piera Angelillo, Roberta Sciarra, Elena Maiolo, Elisa Lucchini, Valeria Tomarchio, Chiara Ghiggi, Sabrina Pelliccia, Miriam Marangon, Luigi Marcheselli, Francesco Zaja. Ibrutinib Dose Modifications in Mantle Cell Lymphoma: an Italian Real-Life Multicenter Experience. Results from the REDOT_MCL Study. ID: PF926, *Poster Presentation*. EHA 2025 Hybrid Congress, June 12-15, Milan, Italy.

Elisa Lucchini, Roberta Sciarra, Valeria Tomarchio, Sabrina Pelliccia, Miriam Marangon, Elena Maiolo, Mattia Novo, Luana Schiattone, Mirko Farina, Greta Scapinello, Francesca Maria Quaglia, Jacopo Olivieri, **Luca Pagliaro**, Piera Angelillo, Lara Mannelli, Chiara Ghiggi, Francesco Zaja. The Role of Stem Cell Transplantation as Consolidation Therapy in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Treated with Checkpoint Inhibitors: Italian Multicenter Experience. ID: S228; *Oral Presentation*. EHA 2025 Hybrid Congress, June 12-15, Milan, Italy.

M. Farina, E. Maiolo, C. Ghiggi, P. Angelillo, M. Novo, F. M. Quaglia, L. Schiattone, L. Mannelli, V. Tomarchio, E. Lucchini, **L. Pagliaro**, G. Scapinello, M. Marangon, S. Pelliccia, R. Sciarra, F. Zaja. A Multi-Center Real-Life Analysis on Patients with Large B-Cell Lymphoma after Failure of CAR-T Cells Therapy. ID: PS2163; *Poster Presentation*. EHA 2025 Hybrid Congress, June 12-15, Milan, Italy.

M. Farina, E. Maiolo, C. Ghiggi, P. Angelillo, M. Novo, F. M. Quaglia, L. Schiattone, L. Mannelli, V. Tomarchio, E. Lucchini, **L. Pagliaro**, G. Scapinello, M. Marangon, S. Pelliccia, R. Sciarra, F. Zaja. A Multi-center Real-

life analysis on patients with Large B-cell Lymphoma after failure of CAR-T Cells Therapy. ID: 971. 51st EBMT Annual Meeting; 30 March-2 April 2025; Florence, Italy.

Amelia Rinaldi, Benedetta Cambo, Mariateresa Giaimo, **Luca Pagliaro**, Raffaella Zamponi, Anna Montanaro, Anna Pessina, Andrea Gherli, Sabrina Bonimini, Gabriella Sammarelli, Roberta Segreto, Giannalisa Todaro, Luisa Craviotto, Roberta La Starza, Giovanni Roti, Lucia Prezioso. Drug Response Profiling as a Bridge to Allogeneic Stem Cell Transplantation in a Relapsed Immature T-ALL with Concomitant AML Clone. BONE MARROW TRANSPLANTATION, vol. 60, pp. 240-241. 51st EBMT Annual Meeting; 30 March-2 April 2025; Florence, Italy.

J. Vanhooren, L. Deneweth, **L. Pagliaro**, Z. Ren, B. Depreter, M. Hofmans, B. De Moerloose, T. Lammens. Nidogen-1, a Novel Player in KMT2A-Rearranged Pediatric Acute Myeloid Leukemia Patients, Expressed in the Leukemic Stem Cell. Blood (2024) 144 (Supplement 1): 6134.doi: 10.1182/blood-2024-200598. 66th ASH Annual Meeting and Exposition, 7-10 December; San Diego, CA, USA.

Pagliaro, Luca; Van Steenberge, Hannah; T'Sas, Sara; Zamponi, Raffaella; Lintermans, Beatrice; Sleenckx, Wouter; Giaimo, Mariateresa; Roti, Giovanni; Van Vlierberghe, Pieter; Goossens, Steven; Pieters, Tim. A Functional Precision Medicine Approach In Preclinical Mantle Cell Lymphoma Models Identifies Selected Target Therapies For Drug Clinical Repurposing. ESH 4th How To Diagnose and Treat Lymphoma, Nov 1-3, 2024; Stockholm, Sweden.

Luca Pagliaro; Mariateresa Giaimo; Raffaella Zamponi; Katia Tragni; Lucas Moron Dalla Tor; Anna Montanaro; Benedetta Cambò; Monica Messina; Valentina Bardelli; Roberta La Starza; Giovanni Roti. Functional omics to guide a precision medicine approach in high-risk T-cell acute lymphoblastic leukemia. EHA-SfPM 2024 Precision Medicine Meeting, September 26-27, Copenhagen, Denmark.

Luca Pagliaro, Hannah Van Steenberge, Sara T'Sas, Raffaella Zamponi, Béatrice Lintermans, Wouter Sleenckx, Giovanni Roti, Pieter Van Vlierberghe, Steven Goossens, Tim Pieters. Drug Profiling in a Preclinical Murine Mantle Cell Lymphoma Mouse Model Identifies Novel Vulnerabilities. EHA 2024 Hybrid Congress; June 13-16, Madrid, Spain.

M Giaimo, **L Pagliaro**, R Zamponi, L Moron Dalla Tor, K Tragni, A Montanaro, B Cambo, M Messina, V Bardelli, R La Starza, C Mecucci, G Roti. Functional Omics in high-risk T-cell Acute Lymphoblastic Leukemia. Haematologica 109, 15-16.

E Simoncini, M Marchesini, A Gherli, L Tor, Moron Dalla, A Montanaro, F Vento, **L Pagliaro**, R Zamponi, R La Starza, C Mecucci, F Quaini, S Colla, G Roti. The intersection of proteogenomic approaches identifies PA2G4 as a new target in 3q26 AML. Haematologica 109, 30-32.

Cerretani E; **Pagliaro L**; Vento F; Montanaro A; Moron Dalla Tor L; Simoncini E; Giaimo M; Gherli A; Zamponi R; D'Antuono A; Tartaglione I; Lorusso B; Quaini F; Rigolin GM; Cuneo A; Roti G. Specific antitumor activity of the new SERCA inhibitor CAD204520 in lymphoproliferative disorders with NOTCH1 PEST domain mutation. 3rd Translational Research Conference on CLL. March 8-10, 2024, Vienna, Austria.

Tim Pieters, **Luca Pagliaro**, Panagiotis Ntziachristos, Pieter Van Vlierberghe, Steven Goossens. SOX11 Drives B1a Lineage Commitment and B1a/MCL-like Lymphoma Formation in Mice. HemaSphere, 2023, 7.Suppl: e255698f. EHA 2023 Hybrid Congress; June 8-10, Frankfurt, Germany. doi: 10.1097/01.HS9.0000967868.25569.8f.

Montanaro A., D'Antuono A., Moron Dalla Tor L., Andrei P., Ciringione A., Cerretani E., Vento F., **Pagliaro L.**, Gherli A., Lorusso B., Simoncini E., Zamponi R., Salvatori C., Todaro G., La Starza R., Mecucci C., Sammarelli G., Marchesini M., Roti G. Identification of the Atypical Protein Kinase WNK1 As a New Target in T-Cell Acute Lymphoblastic Leukemia. Blood (2022) 140 (Supplement 1): 3130–3131. 64th ASH Annual Meeting and Exposition; New Orleans, LA. <https://doi.org/10.1182/blood-2022-163069>.

Marchesini M., Gherli A., Simoncini S., Montanaro A., Thongon N., **Pagliaro L.**, Vento F., Moron Dalla Tor L., Liverani C., Zamponi R., Follini E., Cambò B., Lorusso B., La Starza R., Cuneo A., Mecucci C., Colla S., Quaini F. and Roti G. Orthogonal Proteogenomic Approaches Identify the Druggable PA2G4-MYC Axis in 3q26 AML. Blood (2022) 140 (Supplement 1): 673–674. 64th ASH Annual Meeting and Exposition; New Orleans, LA. <https://doi.org/10.1182/blood-2022-158990>.

Pagliaro L., Moron Dalla Tor L., Vento F., Andrei P., Monica L., Kleissle S., Neuenschwander M., Gherli A., Cerretani E., D'Antuono A., Simoncini E., Montanaro A., Roti G. A Chemotranscriptomic Screening Identifies The Reversal Of Glucocorticoid Resistance in *NOTCH1*-mutated T-ALL. *HemaSphere* 6():p 236-237, June 2022. EHA 2022 Hybrid Congress; June 9-12, Vienna. doi: 10.1097/01.HS9.0000844232.55007.ff.

L Pagliaro, L Moron Dalla Tor, L Monica, P Andrei, F Vento, E Simoncini, Sabrina Kleissle, M Neuenschwander, A Gherli, E Cerretani, A D'Antuono, A Montanaro, G Roti. SERCA Modulation Counteracts Glucocorticoid Resistance In T-ALL. *Haematologica*. 107, 19-19. 17° Congresso Nazionale SIES, March 31, April 1-2. *HAEMATOLOGICA* 107, 19-19

Gene expression at a single-molecule level: implications for myelodysplastic syndromes and acute myeloid leukemia. A commentary by **Luca Pagliaro, MD** and Cristina Mecucci, MD, PhD. October 2021, *BloodOnline.it*, American Society of Hematology.
https://www.bloodonline.it/articles/BL21_10_1/read#tab_commentary.

Pagliaro, L., Tragni, K., and Roti, G. From genomics to chemogenomics in T cell acute lymphoblastic leukemia. *Haematologica*. Vol. 106. No. 10, 2021. 48° Congresso Nazionale SIE e 16° Congresso Nazionale SIES, 2021, October 24-27.

Rinaldi, A., Cambo, B., Prezioso, L., Giaimo, M.T., **Pagliaro, L.**, Dalla Palma, A.B., Sammarelli, G., Lastarza, R., Vallisa, D. and Roti, G. t(10;11)(p13;p14-21) PICALM-MLLT10 acute leukemia: characterization of two cases with different phenotypic presentation. *Haematologica* (Vol. 106, No. 10, pp. 132-132). 48° Congresso Nazionale SIE e 16° Congresso Nazionale SIES, 2021, October 24-27.

M. Marchesini, A. Gherli, A. Montanaro, C. Sorrentino, **L. Pagliaro**, C. Rompietti, F. Rizzi, D. Stilli, A. M Lund Winther, R. La Starza, C. Mecucci, P. Sportoletti, M. Bubltz, W. Dalby-Brown, G. Roti. Inibizione selettiva delle mutazioni di NOTCH1 attraverso il nuovo inibitore di SERCA CAD204520. Abstract C043. 48° Congresso Nazionale SIE e 16° Congresso Nazionale SIES, 2021, October 24-27.

Marchesini M., Gherli G., Lund Winter A.M., Kitara S., Montanaro A., **Pagliaro L.**, Rizzi F., Mecucci C., Stegmaier K., Stilli D., Sportoletti P., Bubltz M., Dalby-Brown W., Roti G.. Selective Blockade of Oncogenic NOTCH1 with the New SERCA Inhibitor CAD204520 in T-cell Acute Lymphoblastic Leukemia. *Clinical Lymphoma Myeloma and Leukemia* 21, S263-S264. [https://doi.org/10.1016/S2152-2650\(21\)01643-8](https://doi.org/10.1016/S2152-2650(21)01643-8).

Matteo Marchesini, Andrea Gherli, Anna Montanaro, Samuel Kitara, Claudia Sorrentino, **Luca Pagliaro**, Anne-Marie Lund Winter, Chiara Rompietti, Donatella Stilli, Federica Rizzi, Kimberly Stegmaier, Paolo Sportoletti, William Dalby-Brown and Giovanni Roti. Targeting the Activating Mutation of NOTCH1 in T-cell Acute Lymphoblastic Leukemia with a New SERCA Inhibitor CAD204520. *Blood* (2019) 134 (Supplement_1): 407. 2019 61th ASH Annual Meeting; Abstract #125616 - oral presentation. <https://doi.org/10.1182/blood-2019-125616>

Matteo Marchesini, Andrea Gherli, Anne-Marie Lund Winter, Samuel Kitara, Anna Montanaro, Chiara Rompietti, Claudia Sorrentino, Donatella Stilli, Federica Rizzi, **Luca Pagliaro**, Kimberly Stegmaier, Paolo Sportoletti, William Dalby-Brown, Giovanni Roti. Selective Blockade of Oncogenic NOTCH1 with the New SERCA inhibitor CAD204520 in T-cell Acute Lymphoblastic Leukemia. *Mol Cancer Ther* (2019) 18 (12_Supplement): B113. 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference - Boston, Massachusetts. <https://doi.org/10.1158/1535-7163.TARG-19-B113>

Matteo Marchesini, Andrea Gherli, Anne-Marie Lund Winter, Anna Montanaro, Chiara Rompietti, Claudia Sorrentino, **Luca Pagliaro**, Paolo Sportoletti, William Dalby-Brown, Giovanni Roti. Targeting oncogenic NOTCH1 in T-cell acute lymphoblastic leukemia with a new selective SERCA inhibitor CAD204520. The 9th International conference Notch Targeting in Cancer, Cyprus, June 26-28. 2019

Matteo Marchesini, Andrea Gherli, Anne-Marie Lund Winter, Laura Patrizi, Samuel Kitara, Anna Montanaro, Chiara Rompietti, Claudia Sorrentino, Donatella Stilli, Federica Rizzi, Caterina Loiacono, **Luca Pagliaro**, Roberta La Starza, Cristina Mecucci, Franco Aversa, Paolo Sportoletti, William Dalby-Brown, Giovanni Roti. Targeting oncogenic NOTCH1 in T-cell acute lymphoblastic leukemia with a new selective SERCA inhibitor CAD204520. 24th EHA annual meeting, Amsterdam, Netherlands, June 12-16, 2019.

Masselli E., Pozzi G., Carubbi C., **Pagliari L.**, Follini E., Cambò B., Crugnola M., Gobbi G., Mirandola P., Aversa F. & Vitale M. (2018). Higher Monocyte Chemoattractant Protein-1 Levels in Myelofibrosis Are Sustained By the rs1024611 Single Nucleotide Polymorphism and Correlate with Disease Subtype and Severity. *Blood*, 132(Suppl 1), 1785, 2018 60th ASH Annual Meeting, San Diego, California. <https://doi.org/10.1182/blood-2018-99-111719>.

L. Pagliaro, G. Sammarelli, F. Russo, C. Plenteda, G. Todaro, L. Pelagatti, L. Notarfranchi, F. Falcioni, F. Aversa, F. Re. Impact of treatment with Idelalisib plus Rituximab on clinical and cytogenetics profile in relapse/refractory CLL: the experience of the University Hospital of Parma. XV Congress of the Italian Society of Experimental Hematology. Rimini, Italy, October 18-20, 2018.

T. Maldacena, A. Montanaro, G. Todaro, F. Russo, C. Plenteda, F. Re, B. Dalla Palma, **L. Pagliaro**, L. Craviotto, M. Gullo, C. Romano, F. Aversa, G. Sammarelli. Prognostic value of cytogenetic aberrations and intratumoral genetic heterogeneity in Chronic Lymphocytic Leukemia (CLL). XV Congress of the Italian Society of Experimental Hematology Rimini, Italy, October 18-20, 2018.

E. Masselli, G. Pozzi, C. Carubbi, B. Cambò, E. Follini, **L. Pagliaro**, M. Crugnola, G. Gobbi, P. Mirandola, F. Aversa, M. Vitale. Functional characterization of the -2518 A/G single nucleotide polymorphism of MCP-1 in myelofibrosis. XV Congress of the Italian Society of Experimental Hematology, Rimini, Italy, October 18-20, 2018.

Ilenia Manfra, Fabrizio Accardi, Benedetta Dalla Palma, **Luca Pagliaro**, Laura Notarfranchi, Federica De Luca, Nicola Giuliani. Effect of Elotuzumab in combination with lenalidomide and dexamethasone as second line of treatment in a Bortezomib refractory multiple myeloma patient. *Eur. J. Oncol.* - Vol. 23 - Suppl. 1 - July 2018 | ISSN 1128-6598.

Francesca Re, **Luca Pagliaro**, Elena Follini, Laura Pelagatti, Ilenia Manfra, Filomena Russo, Caterina Plenteda, Maria Gullo, Claudia Romano, Franco Aversa. Efficacia e tollerabilità di Idelalisib in pazienti affetti da Leucemia Linfatica Cronica recidivata/refrattaria: l'esperienza di Parma. *Eur. J. Oncol.* - Vol. 22 - Suppl. 1; November 2017 | ISSN 1128-6598.

Il sottoscritto Luca Pagliaro dichiara che tutti i fatti riportati nel presente curriculum corrispondono a verità ai sensi e per gli effetti degli artt. 46 e 47 del D.P.R. 445/2000. Il sottoscritto dichiara di essere a conoscenza delle sanzioni penali cui incorre in caso di dichiarazione mendace o contenente dati non più rispondenti a verità, come previsto dall'art. 76 del D.P.R. 28.12.2000, n. 445. Il sottoscritto dichiara di essere a conoscenza dell'art. 75 del D.P.R. 28.12.2000, n. 445, relativo alla decadenza dai benefici eventualmente conseguenti al provvedimento emanato, qualora l'Amministrazione, a seguito di controllo, riscontri la non veridicità del contenuto della suddetta dichiarazione.

Parma, 02/07/2026

Luca Pagliaro, MD, PhD

A handwritten signature in black ink, appearing to be 'Luca Pagliaro', written in a cursive style.